玛仕度肽(Mazdutide)(IBI362/LY-3305677)是信达生物与礼来制药共同推进的一款胰高血糖素样肽-1受体(GLP-1R)/胰高血糖素受体(GCGR)双重激动剂。双方该合作协议的具体条款尚未披露。合作始于2019年8月,临床开发迅速,即将在中国递交第一项新药上市申请。
2023年11月9日,礼来在Clinicaltrials.gov网站上注册了LY3305677(玛仕度肽)用于减重的二期临床试验。 该研究计划入组165例肥胖患者,预计2024年11月初步完成。 玛仕度肽最初由礼来研发,礼来选择自己开发替尔泊肽,而将玛仕度肽授权给信达生物,在美国则暂缓了开发。替尔泊肽已经先后获批治疗二型糖尿病、减重,此次又重...
Mazdutide: A synthetic peptide and dual agonist of GLP-1R and GCGR. CAS Number: 2259884-03-0. Synonyms: IBI362, LY3305677. Purity: ≥98%.
Mazdutide acetate(2259884-03-0 free base)|||OXM-3 acetate|||LY-3305677 acetate|||IBI-362 acetate information, including chemical properties, structure, melting point, boiling point, density, formula, molecular weight, uses, prices, suppliers, SDS and m
IBI362 (LY3305677) is a novel weekly-dose glucagon-like peptide-1 and glucagon receptor dual agonist being developed for the treatment of obesity and type 2 diabetes. The aim of this randomised, placebo-controlled, multiple ascending dose phase 1b study was to evaluate the safety, tolerability...
IBI362(LY3305677) is a novel weekly-dose glucagon-like peptide-1 and glucagon receptor dual agonist being developed for the treatment of obesity and type 2 diabetes. The aim of this randomised, placebo-controlled, multiple ascending dose phase 1b study was to evaluate the safety, tolerability,...
信达生物IBI362临床试验,比较IBI362注射液(Mazdutide、LY3305677)和度拉糖肽治疗二甲双胍单药或二甲双胍联合钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂/磺脲类药物治疗血糖控制不佳的2型糖尿病疗效的III期临床试验 试验目的 验证IBI362组第28周的糖化血红蛋白(glycatedhemoglobinA1C,HbA1c)水平较基线的变化非劣效于度拉...